BlackRock
PCSA icon

BlackRock’s Processa Pharmaceuticals PCSA Stock Holding History

BlackRock’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$98 – 5361
2023
Q4 		$98 Hold
1
– – ﹤0.01% 5331
2023
Q3 		$73 Hold
1
– – ﹤0.01% 5401
2023
Q2 		$146 Sell
1
-58
-98% -$17.1K ﹤0.01% 5457
2023
Q1 		$14.7K Buy
59
+2
+4% +$806 ﹤0.01% 5285
2022
Q4 		$31.3K Buy
57
+1
+2% +$966 ﹤0.01% 5316
2022
Q3 		$63K Sell
56
-1
-2% -$1.47K ﹤0.01% 5305
2022
Q2 		$81K Sell
57
-1
-2% -$1.37K ﹤0.01% 5295
2022
Q1 		$87K Sell
58
-3
-5% -$5.71K ﹤0.01% 5309
2021
Q4 		$149K Buy
61
+7
+13% +$21.7K ﹤0.01% 5169
2021
Q3 		$232K Sell
54
-1
-2% -$3.42K ﹤0.01% 4948
2021
Q2 		$226K Buy
+55
New +$213K ﹤0.01% 4878

Other funds holding PCSA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

BlackRock's PCSA Position: Q1 2024 in Review

BlackRock sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 1 share — an estimated $98 sold.

BlackRock first reported a position in PCSA in Q2 2021 and held it in 11 quarters. The position peaked at $232K in Q3 2021. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

  • BlackRock reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • BlackRock sold 1 Processa Pharmaceuticals share in Q1 2024, an estimated $98.
  • BlackRock first reported a position in Processa Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • BlackRock's Processa Pharmaceuticals position peaked at $232K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.